CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push

RevuforjPositive
AI Analysis

Summary

Syndax Pharmaceuticals is expanding its commercial pipeline beyond Revuforj with development programs in lung cancer and myelofibrosis indications.

Importance:4/10
Sentiment:
0.50
pipeline_expansiononcologylung_cancermyelofibrosis
Related Companies

Read the original article

Published by yahoo_finance on July 14, 2026 8:02 PM

Read Original